Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1693) 1693
science & technology (1579) 1579
life sciences & biomedicine (1476) 1476
erlotinib hydrochloride (1287) 1287
oncology (1004) 1004
erlotinib (763) 763
quinazolines - pharmacology (734) 734
lung neoplasms - drug therapy (722) 722
female (716) 716
receptor, epidermal growth factor - antagonists & inhibitors (630) 630
carcinoma, non-small-cell lung - drug therapy (615) 615
cell line, tumor (594) 594
male (591) 591
animals (552) 552
protein kinase inhibitors - pharmacology (550) 550
biological and medical sciences (547) 547
medical sciences (542) 542
quinazolines - therapeutic use (491) 491
middle aged (469) 469
antineoplastic agents - pharmacology (455) 455
tumors (453) 453
aged (441) 441
receptor, epidermal growth factor - genetics (400) 400
mice (391) 391
lung neoplasms - pathology (377) 377
pharmacology & pharmacy (375) 375
pharmacology. drug treatments (364) 364
antineoplastic agents (358) 358
antineoplastic agents - therapeutic use (355) 355
mutation (355) 355
receptor, epidermal growth factor - metabolism (351) 351
quinazolines - administration & dosage (344) 344
protein kinase inhibitors - therapeutic use (342) 342
cancer (337) 337
adult (334) 334
erlotinib hydrochloride - pharmacology (326) 326
lung neoplasms - genetics (326) 326
epidermal growth factor (313) 313
carcinoma, non-small-cell lung - pathology (292) 292
lung cancer (290) 290
treatment outcome (271) 271
antineoplastic combined chemotherapy protocols - therapeutic use (267) 267
carcinoma, non-small-cell lung - genetics (261) 261
lung cancer, non-small cell (257) 257
cell proliferation - drug effects (239) 239
egfr (228) 228
chemotherapy (224) 224
gefitinib (210) 210
respiratory tract diseases (209) 209
lung neoplasms - metabolism (208) 208
quinazolines - adverse effects (206) 206
care and treatment (204) 204
tyrosine (202) 202
xenograft model antitumor assays (198) 198
analysis (195) 195
aged, 80 and over (194) 194
drug resistance, neoplasm (192) 192
mice, nude (192) 192
signal transduction - drug effects (192) 192
apoptosis - drug effects (186) 186
pneumology (186) 186
tumors of the respiratory system and mediastinum (184) 184
research (181) 181
erbb receptors - antagonists & inhibitors (179) 179
epidermal growth factor receptor (172) 172
signal transduction (162) 162
disease-free survival (157) 157
kinases (155) 155
carcinoma, non-small-cell lung - metabolism (152) 152
antibodies, monoclonal, humanized (149) 149
non-small cell lung cancer (146) 146
erlotinib hydrochloride - therapeutic use (145) 145
adenocarcinoma - drug therapy (144) 144
drug synergism (144) 144
neoplasms (144) 144
dose-response relationship, drug (141) 141
cell biology (140) 140
medicine & public health (140) 140
epidermal growth factor receptors (136) 136
cetuximab (129) 129
apoptosis (128) 128
erlotinib hydrochloride - administration & dosage (128) 128
protein kinase inhibitors - administration & dosage (127) 127
drug therapy (126) 126
drug resistance, neoplasm - genetics (121) 121
health aspects (121) 121
pharmacology/toxicology (121) 121
drug resistance, neoplasm - drug effects (119) 119
phosphorylation (113) 113
quinazolines - pharmacokinetics (113) 113
antineoplastic agents - administration & dosage (112) 112
cancer research (111) 111
deoxycytidine - analogs & derivatives (111) 111
erbb receptors - genetics (111) 111
cell survival - drug effects (110) 110
genetic aspects (108) 108
protein kinase inhibitors - adverse effects (107) 107
erbb receptors - metabolism (106) 106
pancreatic neoplasms - drug therapy (105) 105
antineoplastic agents - adverse effects (102) 102
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1820) 1820
Chinese (10) 10
Russian (6) 6
French (5) 5
Japanese (5) 5
Hungarian (4) 4
German (3) 3
Spanish (2) 2
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Erlotinib hydrochloride
by Dowell, Jonathan and Minna, John D and Kirkpatrick, Peter
Nature reviews. Drug discovery, ISSN 1474-1776, 01/2005, Volume 4, Issue 1, pp. 13 - 14
Erlotinib Hydrochloride | Humans | Receptor, Epidermal Growth Factor - classification | Receptor, Epidermal Growth Factor - drug effects | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Clinical Trials, Phase III as Topic | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Drug Design | Antineoplastic Agents - pharmacology | Quinazolines - chemistry | Drug Screening Assays, Antitumor - methods | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - epidemiology | Treatment Outcome | Antineoplastic Agents - chemistry | Randomized Controlled Trials as Topic | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Delivery Systems - trends | Quinazolines - pharmacology | Drug Delivery Systems - methods | Expert Testimony | Pharmaceutical industry | Biotechnology industry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients
by Reis, Rafael and Labat, Laurence and Allard, Marie and Boudou-Rouquette, Pascaline and Chapron, Jeanne and Bellesoeur, Audrey and Thomas-Schoemann, Audrey and Arrondeau, Jennifer and Giraud, Frédérique and Alexandre, Jérôme and Vidal, Michel and Goldwasser, François and Blanchet, Benoît
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 09/2018, Volume 158, pp. 174 - 183
Therapeutic drug monitoring | Tyrosine kinase inhibitor | LC–MS/MS | Lung cancer | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Chemistry, Analytical | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Chromatography, High Pressure Liquid | Drug Monitoring - methods | Tandem Mass Spectrometry | Pyrazoles - blood | Sensitivity and Specificity | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Piperazines - blood | Pyrazoles - pharmacology | Pyridines - therapeutic use | Crizotinib | Limit of Detection | Reproducibility of Results | ErbB Receptors - antagonists & inhibitors | Drug Stability | Indoles - blood | Piperazines - therapeutic use | Piperazines - pharmacology | Protein Kinase Inhibitors - blood | Quinazolines - blood | Erlotinib Hydrochloride - blood | Pyridines - blood | Afatinib | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Erlotinib Hydrochloride - pharmacology | Antineoplastic Agents - blood | Carcinoma, Non-Small-Cell Lung - blood | Indoles - therapeutic use | Erlotinib Hydrochloride - therapeutic use | Lung Neoplasms - blood | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Tyrosine | Lung cancer, Small cell | Liquid chromatography | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Epidermal growth factor | Erlotinib | Analysis | Formic acid | Nitriles | Lymphomas | Precipitation (Meteorology) | Health aspects | Mass spectrometry | Vascular endothelial growth factor | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Use of roller compaction and fines recycling process in the preparation of erlotinib hydrochloride tablets
by Hwang, Kyu-Mok and Kim, Sang-Yeop and Nguyen, Thi-Tram and Cho, Cheol-Hee and Park, Eun-Seok
European journal of pharmaceutical sciences, ISSN 0928-0987, 04/2019, Volume 131, pp. 99 - 110
Roller compaction | Dry granulation | Bioequivalence | Powder rheometer | Recompaction | Compaction simulator | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Usage | Powders | Erlotinib | Laboratories | Pharmacy | Drugstores | Laboratory equipment | Equipment and supplies | Production processes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride
by Vrignaud, Sandy and Hureaux, José and Wack, Séverine and Benoit, Jean-Pierre and Saulnier, Patrick
International journal of pharmaceutics, ISSN 0378-5173, 10/2012, Volume 436, Issue 1-2, pp. 194 - 200
PIT method | Sorbitan esters | Tyrosine kinase inhibitor | BxPC-3 cells | Lipid nanoparticles | Polyoxyethylene sorbitan fatty acid esters | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Erlotinib Hydrochloride | Cell Survival - drug effects | Nanoparticles - chemistry | Humans | Drug Carriers - administration & dosage | Antineoplastic Agents - administration & dosage | Antineoplastic Agents - chemistry | Drug Carriers - chemistry | Triglycerides - chemistry | Triglycerides - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - chemistry | Surface-Active Agents - administration & dosage | Micelles | Cell Line, Tumor | Quinazolines - administration & dosage | Nanoparticles - administration & dosage | Surface-Active Agents - chemistry | Quinazolines - chemistry | Antimitotic agents | Tyrosine | Esters | Antineoplastic agents | Fatty acids | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma
by Majumder, Poulami and Baxa, Ulrich and Walsh, Scott T. R and Schneider, Joel P
Angewandte Chemie (International ed.), ISSN 1433-7851, 11/2018, Volume 57, Issue 46, pp. 15040 - 15044
self-assembly | combination therapy | peptides | hydrogels | doxorubicin | Physical Sciences | Chemistry | Chemistry, Multidisciplinary | Science & Technology | Anthracyclines | Peptides | Glioblastoma multiforme | Brain tumors | Brain | Epidermal growth factor receptors | Hydrogels | Fibrils | Glioblastoma | Crosslinking | Synergism | Doxorubicin | New combinations | Temporal resolution | Deoxyribonucleic acid--DNA | Cancer | Index Medicus | Self-assembly | Hydrogel | Combination therapy | Peptide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Inhibition of ABCB1 and ABCG2 at the Mouse Blood–Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib
by Traxl, Alexander and Mairinger, Severin and Filip, Thomas and Sauberer, Michael and Stanek, Johann and Poschner, Stefan and Jäger, Walter and Zoufal, Viktoria and Novarino, Gaia and Tournier, Nicolas and Bauer, Martin and Wanek, Thomas and Langer, Oliver
Molecular pharmaceutics, ISSN 1543-8384, 03/2019, Volume 16, Issue 3, pp. 1282 - 1293
blood-brain barrier | P-glycoprotein | tyrosine kinase inhibitors | breast cancer resistance protein | C]erlotinib | [ | positron emission tomography | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Capillary Permeability - physiology | Quinolines - blood | ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism | Cyclosporine - pharmacology | Quinolines - administration & dosage | Quinolines - pharmacology | Brain - metabolism | Cyclosporine - blood | Tissue Distribution | Radiopharmaceuticals - metabolism | Drug Interactions | Female | Models, Animal | ATP Binding Cassette Transporter, Subfamily G, Member 2 - antagonists & inhibitors | Cyclosporine - metabolism | Radiopharmaceuticals - pharmacology | Erlotinib Hydrochloride - administration & dosage | Solubility | Positron-Emission Tomography - methods | Protein Kinase Inhibitors - blood | Blood-Brain Barrier - metabolism | Erlotinib Hydrochloride - blood | Radiopharmaceuticals - blood | Quinolines - metabolism | Radiopharmaceuticals - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Protein Kinase Inhibitors - administration & dosage | Animals | Erlotinib Hydrochloride - pharmacology | Cyclosporine - administration & dosage | Erlotinib Hydrochloride - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Protein Kinase Inhibitors - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text QbD based approach for formulation development of spray dried microparticles of erlotinib hydrochloride for sustained release
by Soni, Govind and Yadav, Khushwant S and Gupta, M.K
Journal of drug delivery science and technology, ISSN 1773-2247, 06/2020, Volume 57, p. 101684
PCL | Spray drying | Erlotinib hydrochloride | Sustained release | QbD | Microparticles | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy
by Quintanal-Villalonga, Alvaro and Molina-Pinelo, Sonia and Cirauqui, Cristina and Ojeda-Márquez, Laura and Marrugal, Ángela and Suarez, Rocío and Conde, Esther and Ponce-Aix, Santiago and Enguita, Ana Belén and Carnero, Amancio and Ferrer, Irene and Paz-Ares, Luis
Journal of thoracic oncology, ISSN 1556-0864, 04/2019, Volume 14, Issue 4, pp. 641 - 655
combined inhibition | EGFR | FGFR1 | cooperation | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Piperazines - administration & dosage | Lung Neoplasms - drug therapy | Humans | ErbB Receptors - genetics | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Male | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Carcinogenesis | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Benzamides - administration & dosage | Transfection | Female | Benzamides - pharmacology | Acrylamides - pharmacology | Aniline Compounds - administration & dosage | Pyrazoles - pharmacology | Lung Neoplasms - genetics | Aniline Compounds - pharmacology | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Lung Neoplasms - enzymology | Pyrimidines - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Pyrimidines - pharmacology | Piperazines - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Drug Synergism | Xenograft Model Antitumor Assays | Pyrazoles - administration & dosage | Animals | Acrylamides - administration & dosage | Phenylurea Compounds - administration & dosage | Mice, Nude | ErbB Receptors - biosynthesis | Erlotinib Hydrochloride - pharmacology | Cell Line, Tumor | Mice | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Enzyme Activation | Receptor, Fibroblast Growth Factor, Type 1 - biosynthesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
by Prahallad, Anirudh and Sun, Chong and Huang, Sidong and Di Nicolantonio, Federica and Salazar, Ramon and Zecchin, Davide and Beijersbergen, Roderick L and Bardelli, Alberto and Bernards, René
Nature (London), ISSN 0028-0836, 03/2012, Volume 483, Issue 7387, pp. 100 - 104
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Chemotherapy | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - agonists | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | RNA Interference | Colorectal Neoplasms - drug therapy | HEK293 Cells | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cetuximab | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Colorectal Neoplasms - enzymology | Antibodies, Monoclonal - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Drug Synergism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Feedback, Physiological - drug effects | Indoles - therapeutic use | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Proteins | Library collections | Studies | Phosphorylation | Kinases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Combination of ruthenium(II)-arene complex [Ru(η-p-cymene)Cl(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity
by Berndsen, Robert H and Weiss, Anea and Abdul, U Kulsoom and Wong, Tse J and Meraldi, Patrick and Griffioen, Arjan W and Dyson, Paul J and Nowak-Sliwinska, Patrycja
Scientific reports, ISSN 2045-2322, 02/2017, Volume 7, Issue 1, pp. 43005 - 43005
Journal Article | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Human Umbilical Vein Endothelial Cells | Neovascularization, Physiologic - drug effects | Humans | Erlotinib Hydrochloride - chemistry | Ovarian Neoplasms - pathology | Cellular Senescence - drug effects | Antineoplastic Agents - therapeutic use | Chorioallantoic Membrane - physiology | Chorioallantoic Membrane - drug effects | Organometallic Compounds - therapeutic use | Female | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Ovarian Neoplasms - drug therapy | Cell Survival - drug effects | Antineoplastic Agents - chemistry | Drug Synergism | Cell Movement - drug effects | Animals | Mice, Nude | Chickens | Erlotinib Hydrochloride - pharmacology | Cell Line, Tumor | Organometallic Compounds - chemistry | Erlotinib Hydrochloride - therapeutic use | Mice | Organometallic Compounds - pharmacology | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer
by Li, Fengqiao and Mei, Hao and Gao, Yu and Xie, Xiaodong and Nie, Huifang and Li, Tao and Zhang, Huijuan and Jia, Lee
Biomaterials, ISSN 0142-9612, 11/2017, Volume 145, pp. 56 - 71
Hypoxia | Liposomal complexes | NSCLC | Drug resistance | PFOB | Engineering | Materials Science | Technology | Engineering, Biomedical | Materials Science, Biomaterials | Science & Technology | Immunohistochemistry | Lung Neoplasms - drug therapy | Oxygen - pharmacology | Hypoxia - drug therapy | Oxygen - therapeutic use | Humans | Lung Neoplasms - pathology | Drug Delivery Systems | Receptor, Epidermal Growth Factor - metabolism | Cell Death - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Tissue Distribution - drug effects | Endocytosis - drug effects | Erlotinib Hydrochloride - administration & dosage | Aptamers, Nucleotide - chemistry | Oxygen - administration & dosage | Animals | Mice, Nude | Models, Biological | Erlotinib Hydrochloride - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Liposomes | Drug Resistance, Neoplasm - drug effects | Drugs | Chemotherapy | Drug delivery systems | Erlotinib | Drug therapy | Lung cancer, Non-small cell | Vehicles | Cancer | Prevention | Metastasis | Catalysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights